Nussbaum Ran 4/A
4/A · UroGen Pharma Ltd. · Filed Feb 28, 2023
Insider Transaction Report
Form 4/AAmended
Nussbaum Ran
Director
Transactions
- Exercise/Conversion
Ordinary Shares
2022-06-06$5.00/sh+1,030$5,150→ 1,434,958 total(indirect: Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd.) - Exercise/Conversion
Stock Option (right to buy)
2022-06-06−1,030→ 0 total(indirect: By Partnership)Exercise: $5.00From: 2015-09-01Exp: 2022-09-01→ Ordinary Shares (1,030 underlying)
Footnotes (2)
- [F1]On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares.
- [F2]On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022.